CordenPharma Announces Expanded Aseptic & Oral Development Capabilities
As part of a long term strategy to meet increasing customer demands, CordenPharma has completed two additional key investments to strengthen its development and manufacturing capabilities for Drug Product service offerings across its Highly Potent, Oncology, and Injectables Platforms.
First, CordenPharma announced the completion and approval of its small-scale aseptic filling line in CordenPharma Caponago (IT). This addition to the existing terminal sterilization capabilities of the manufacturing facility will support customer development and commercial programs by providing expert service in aseptic-filling of liquid and lyophilized vials and prefilled syringes for small molecules and peptides.
CordenPharma is additionally pleased to announce the completion and approval of expanded Development Capabilities (CTD2) for mid-scale (up to 20 kg) contained capacity of highly potent and oncology oral dosage forms in its CordenPharma Plankstadt (DE) manufacturing facility. This new and expanded capability provides customers a complete offering in the contained manufacturing of oral dosage from grams to 150 Kg.
“These new investments in oral and aseptic development capacities strengthen our ability to serve customers earlier in the pharmaceutical value chain. They are a clear indication of our overall commitment in responding to customers’ needs and are perfect complements to our existing API and Drug Product service offerings within our Highly Potent, Oncology, and Injectables Platforms,” said Ernesto Petroselli, President of CordenPharma International. “In addition, we anticipate further capacity expansion in the second half of 2016 by the completion of a second pharmaceutical oncology suite in CordenPharma Latina (IT) to provide extended supply chain manufacturing services spanning development to commercial scale.”
These expansions enhance CordenPharma’s service offerings in the sterile and containment fields spanning from development to well-established worldwide commercial supply.
CordenPharma, a pharmaceutical brand of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a network of fully-inspected cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent, Small Molecules, Antibiotics, Oncology – CordenPharma experts translate complex ideas at any stage of development into high-value products. For more information, visit www.cordenpharma.com/contact-us/.
Total Page Views: 856
